The Food and Drug Administration approved the first disease-modifying treatment for Alexander disease on Thursday, giving patients with the ultra-rare and fatal neurological disorder a therapy for the first time since the condition was identified more than 70 years ago.
The drug, developed by Ionis Pharmaceuticals and sold under the brand name Zanvastro (chemical name zilganersen), is an antisense oligonucleotide — a lab-made strand of genetic material designed to bind to and break down the messenger RNA that produces GFAP, the abnormal protein that drives the disease. It is delivered by injection into the spinal fluid once every three months and is approved for both children and adults.
A Disease With No Prior Treatment
Alexander disease is caused by mutations in the GFAP gene and damages astrocytes, support cells in the brain and spinal cord, leading to seizures, developmental delays, muscle weakness and dangerously elevated pressure inside the skull. It is thought to affect roughly 1 in 1 to 3 million people worldwide, with an estimated 300 patients in the United States — a population small enough that, until now, no pharmaceutical company had brought a targeted therapy through clinical trials to approval.
In the pivotal placebo-controlled trial of 49 participants, patients who received zilganersen showed statistically significant stabilization in walking speed at 61 weeks, while patients on placebo continued to decline — a 33 percent drop in the control group compared with essentially no change in the treated group. Blood tests confirmed the drug was reaching its molecular target and reducing GFAP production as intended, and researchers saw early signals that treatment begun in young children might improve motor function rather than merely halt its decline. The most common side effects were mild to moderate, including vomiting, back pain and cough, with serious adverse events occurring more often in the untreated group.
Approval Ahead of Schedule
The FDA's decision came more than two weeks ahead of its September 22 target review date. Ionis Chief Executive Brett Monia signaled the approval is part of a broader push into neurology drug development at the company.
That's priority now and that pipeline is going to grow. We're expecting additional neurology medicines to enter the clinic in the near future.
Brett Monia, CEO, Ionis Pharmaceuticals
The therapy carries a list price of $285,000 per dose, or roughly $1.14 million a year, reflecting the steep costs typical of treatments for diseases affecting only a few hundred patients nationwide. Analysts have projected peak US sales of around $160 million annually by 2040 — a modest figure by pharmaceutical-industry standards, but one that underscores how the approval was driven as much by unmet medical need as by commercial scale.
